

FILE 'HOME' ENTERED AT 17:55:14 ON 08 DEC 2001

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'USPATFULL' ENTERED AT 17:55:31 ON 08 DEC 2001

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Dec 2001 (20011206/PD)

FILE LAST UPDATED: 6 Dec 2001 (20011206/ED)

HIGHEST GRANTED PATENT NUMBER: US6249914

HIGHEST APPLICATION PUBLICATION NUMBER: US2001049836

CA INDEXING IS CURRENT THROUGH 6 Dec 2001 (20011206/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Dec 2001 (20011206/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2001

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2001

>>> Page images are available for patents from 1/1/1998. Patents <<<
>>> and applications are typically loaded on the day of publication.<<<
>>> Page images are available for display by the following day. <<<
>>> Image data for the /FA field are available the following update.<<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (anti-sense)

218619 ANTI
334268 SENSE
L1 6895 (ANTI-SENSE)
(ANTI(W)SENSE)

=> s (hcv or hepatitis c virus)

1021 HCV
12595 HEPATITIS
1624362 C
36886 VIRUS
895 HEPATITIS C VIRUS
(HEPATITIS(W)C(W)VIRUS)
L2 1288 (HCV OR HEPATITIS C VIRUS)

=> s l1 and l2

=> s' (sabin 2)

304 SABIN
2961080 2
L4 9 (SABIN 2)
(SABIN(W) 2)

=> s 12 and 14

L5 0 L2 AND L4

=> s 12 and 14

L6 0 L2 AND L4

=> s sabin

L7 304 SABIN

=> s 17 and 13

L8 8 L7 AND L3

=> d 18 1-8 ab bib

L8 ANSWER 1 OF 8 USPATFULL

AB The present invention provides methods of treating hepatitis C
infections comprising the step of administering a vector construct
which

directs the expression of at least one immunogenic portion of a
hepatitis C antigen, such that an immune response is generated. Also
provided are vector constructs which direct the expression of at least
one portion of a hepatitis C antigen, as well as recombinant viruses
which carry such vector constructs.

AN 2001:167936 USPATFULL

TI Hepatitis therapeutics

IN Jolly, Douglas J., Leucadia, CA, United States
Chang, Stephen M. W., Poway, CA, United States
Lee, William T. L., Carlsbad, CA, United States
Townsend, Kay, Encinitas, CA, United States
O'Dea, Joanne, La Jolla, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 6297048 B1 20011002

AI US 1995-483511 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,
now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on
5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US
1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned
Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992,
now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Schwartzman, Robert A.

LREP Blackburn, Robert P., McMasters, David, Dollard, Anne S.

CLMN Number of Claims: 7

ECL Exemplary Claim: 6

DRWN 21 Drawing Figure(s); 17 Drawing Page(s)

LN.CNT 3732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 8 USPATFULL

AB The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-.tau.) polypeptide and a C-terminal region derived from another type I interferon polypeptide, such as IFN-.alpha. or IFN-.beta.. The fusion proteins exhibit reduced cytotoxicity as compared to the corresponding unmodified type I interferons.

AN 2001:8162 USPATFULL

TI Hybrid interferon .tau./type I interferon polypeptides

IN Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States

PA University of Florida, Gainesville, FL, United States (U.S. corporation)

PI US 6174996 B1 20010116

AI US 1998-45467 19980320 (9)

RLI Continuation of Ser. No. US 1995-455021, filed on 31 May 1995, now patented, Pat. No. US 5958402 Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363 Continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Fitzgerald, David L.

LREP Petithory, Joanne R., Mohr, Judy M.Iota Pi Law Group

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 28 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 3067

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 8 USPATFULL

AB The invention provides antitumor therapeutic methods employing bovine or

ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..

AN 1999:116974 USPATFULL

TI Antitumor therapy using ovine or bovine interferon-tau

IN Bazer, Fuller Warren, College Station, TX, United States
Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Ott, Troy Lee, Bryan, TX, United States
Van Heeke, Gino, Witterswil, Switzerland

PA University of Florida, Gainesville, FL, United States (U.S. corporation)

PI US 5958402 19990928

AI US 1995-455021 19950531 (8)

RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363 which is a continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned, said Ser. No. US 139891 which is a continuation-in-part of Ser. No. US 1992-969890,

filed on 30 Oct 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Fitzgerald, David L.

LREP Sholtz, Charles K., Petithory, Joanne R.Dehlinger & Associates

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 25 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 3848

L8 ANSWER 4 OF 8 USPATFULL

AB The invention provides antiviral therapeutic methods employing bovine
or

ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..

AN 1999:99371 USPATFULL

TI Antiviral therapy using ovine or bovine interferon-tau

IN Bazer, Fuller Warren, College Station, TX, United States
Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Ott, Troy Lee, Bryan, TX, United States
Heeke, Gino Van, Witterswil, Switzerland

PA University of Florida, Gainesville, FL, United States (U.S.
corporation)

PI US 5942223 19990824

AI US 1995-455524 19950531 (8)

RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now
patented, Pat. No. US 5705363 which is a continuation-in-part of Ser.
No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1989-318050, filed on 2 Mar 1989, now abandoned, said Ser. No. US
139891 which is a continuation-in-part of Ser. No. US 1992-969890,

filed

on 30 Oct 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Fitzgerald, David L.

LREP Scholtz, Charles K., Petithory, Joanne R. Dehlinger & Associates

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 25 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 3847

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 8 USPATFULL

AB The present invention describes hybrid interferon fusion polypeptides
formed of a first segment that contains the N-terminal amino acid
sequence of an interferon-tau polypeptide, and a second segment that
contains the C-terminal amino acid sequence of a non-tau interferon

type

I polypeptide. The two segments are joined in the region of a mature
interferon polypeptide between about residues 8 and 37. Also described
are nucleic acid sequences encoding such interferon fusion

polypeptides,

expression vectors containing such sequences, and therapeutic
applications of the interferon fusion polypeptides. The therapeutic
applications include antiviral and anticellular proliferation
applications. One advantage of the interferon fusion polypeptides of

the

present invention is that they do not have cytotoxic side-effects when
used to treat cells.

AN 1999:96237 USPATFULL

TI Hybrid interferon tau/alpha polypeptides, their recombinant production,
and methods using them

IN Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Subramaniam, Prem Shankar, Gainesville, FL, United States

PA University of Florida, Gainesville, FL, United States (U.S.
corporation)

PI US 5939286 19990817
AI US 1996-631328 19960412 (8)
RLI Continuation-in-part of Ser. No. US 1995-438753, filed on 10 May 1995,
now patented, Pat. No. US 5705363
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Petithory, Joanne R., Sholtz, Charles K., Dehlinger, Peter J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 27 Drawing Page(s)
LN.CNT 4631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 8 USPATFULL

AB The present invention describes the production of interferon-.tau.
proteins and polypeptides derived therefrom. The antiviral and
anticellular proliferation properties of these proteins and
polypeptides
are disclosed. One advantage of the proteins of the present invention
is
that they do not have cytotoxic side-effects when used to treat cells.
Structure/function relationships for the interferon-.tau. protein are
also described. In one aspect, the invention includes ovine
interferon-.tau.. In another aspect the invention includes multiple
forms of human interferon-.tau..

AN 1998:39242 USPATFULL

TI Human interferon .tau. proteins and methods of use

IN Imakawa, Kazuhiko, Derby, KS, United States

PA The Women's Research Institute, Wichita, KS, United States (U.S.
corporation)

PI US 5738845 19980414

AI US 1995-443883 19950531 (8)

RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995 which is
a

continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1992-847741, filed on 9 Mar 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989,
now abandoned , said Ser. No. US 1993-139891, filed on 19 Oct 1993

which

is a continuation-in-part of Ser. No. US 1992-969890, filed on 30 Oct
1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Fitzgerald, David L.

LREP Sholtz, Charles K., Fabian, Gary R., Dehlinger, Peter J.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1,7,10

DRWN 25 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 3618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 8 USPATFULL

AB The present invention describes the production of interferon-.tau.
proteins and polypeptides derived therefrom. The antiviral and
anticellular proliferation properties of these proteins and
polypeptides
are disclosed. One advantage of the proteins of the present invention
is
that they do not have cytotoxic side-effects when used to treat cells.
Structure/function relationships for the interferon-.tau. protein are
also described. In one aspect, the invention includes ovine
interferon-.tau.. In another aspect the invention includes multiple
forms of human interferon-.tau..

AN 1998:1650 USPATFULL
 TI Recombinant production of human interferon .tau. polypeptides and nucleic acids
 IN Imakawa, Kazuhiko, Derby, KS, United States
 PA The Women's Research Institute, Wichita, KS, United States (U.S. corporation)
 PI US 5705363 19980106
 AI US 1995-438753 19950510 (8)
 RLI Continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned, said Ser. No. US -139891 which is a continuation-in-part of Ser. No. US 1992-969890, filed on 30 Oct 1992, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Fitzgerald, David L.
 LREP Sholtz, Charles K., Fabian, Gary R., Dehlinger, Peter J.
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 28 Drawing Figure(s); 21 Drawing Page(s)
 LN.CNT 3635
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 8 USPATFULL
 AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.
 AN 97:117939 USPATFULL
 TI Methods and compositions for inhibiting production of replication competent virus
 IN Klump, Wolfgang M., Del Mar, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 PA Chiron Corporation, United States (U.S. corporation)
 PI US 5698446 19971216
 AI US 1994-305699 19940907 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Guzo, David
 LREP Kruse, Norman J., Blackburn, Robert P.
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN 23 Drawing Figure(s); 10 Drawing Page(s)
 LN.CNT 2090
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (IRBS or internal ribosome binding site)

20 IRBS
 699231 INTERNAL
 7424 RIBOSOME
 146168 BINDING
 211359 SITE
 26 INTERNAL RIBOSOME BINDING SITE
 (INTERNAL(W) RIBOSOME(W) BINDING(W) SITE)
 L9 45 (IRBS OR INTERNAL RIBOSOME BINDING SITE)

=> s 12 and 19

L10 6 L2 AND L9

=> s l10 and l1

L11 2 L10 AND L1

=> d l11 1-2 ab bib

L11 ANSWER 1 OF 2 USPATFULL

AB Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.

AN 1998:36597 USPATFULL

TI Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells

IN Chada, Sunil, 1542 Enchantment Ave., Vista, CA, United States 92083
Dubensky, Jr., Thomas W., 12729 via Felino, Del Mar, CA, United States 92014

PI US 5736388 19980407

AI US 1994-366522 19941230 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Chambers, Jasmine C.; Assistant Examiner: Priebe, Scott D.

LREP Kruse, Norman J., Blackburn, Robert P.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 2215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 2 USPATFULL

AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.

AN 97:117939 USPATFULL

TI Methods and compositions for inhibiting production of replication competent virus

IN Klump, Wolfgang M., Del Mar, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

PA Chiron Corporation, United States (U.S. corporation)

PI US 5698446 19971216

AI US 1994-305699 19940907 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Guzo, David

LREP Kruse, Norman J., Blackburn, Robert P.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 2090

=> d 110 1-6 ab bib

L10 ANSWER 1 OF 6 USPATFULL

AB Peptides and RNA oligonucleotides and methods of use for the inhibition of translation of an mRNA, which is initiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, are disclosed. Peptides comprising the La autoantigen binding domain (LAP) are disclosed. LAP peptides alone or in combination with inhibitor RNA oligonucleotides (IRNA) may be used as antiviral agents

to inhibit internal ribosome entry site (IRES) mediated viral replication.

AN 2001:158455 USPATFULL

TI Interference with viral IRES-mediated translation by a small yeast RNA reveals critical RNA-protein interactions

IN Das, Saumitra, Los Angeles, CA, United States

Dasgupta, Asim, Los Angeles, CA, United States

PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

PI US 6291637 B1 20010918

AI US 1999-316630 19990521 (9)

RLI Continuation-in-part of Ser. No. US 1997-817953, filed on 6 Oct 1997, now patented, Pat. No. US 5989904 Continuation-in-part of Ser. No. US 1994-321427, filed on 11 Oct 1994, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: McGarry, Sean

LREP Morrison & Foerster LLP

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 2234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 6 USPATFULL

AB Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences,

an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In

addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector

constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.

AN 2000:4680 USPATFULL

TI Crossless retroviral vectors

IN Respass, James G., San Diego, CA, United States

DePolo, Nicholas J., Solana Beach, CA, United States

Chada, Sunil, Missouri City, TX, United States

Sauter, Sybille, Del Mar, CA, United States

Bodner, Mordechai, San Diego, CA, United States

Driver, David A., San Diego, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 6013517 20000111

AI US 1997-850961 19970505 (8)

RLI Continuation-in-part of Ser. No. US 1996-721327, filed on 26 Sep 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-643411, filed on 6 May 1996, now abandoned which is a

~~continuation-in-part of Ser. No. US 1995-437465, filed on 9 May 1995,~~
~~now abandoned which is a continuation-in-part of Ser. No. US~~
~~1994-240030, filed on 9 May 1994, now abandoned~~

DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Blackburn, Robert P.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 6 USPATFULL

AB A method to inhibit translation of an mRNA, which is initiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, is disclosed. The method comprises a step of providing, in an in vitro, or in vivo system that is capable of translating the mRNA, an inhibitory effective amount of a molecule that selectively binds to the protein factor, thereby preventing that factor from binding to the mRNA. The inhibitor molecule is an RNA oligonucleotide consisting of less than 35 nucleotides or a structural mimic of such an RNA oligonucleotide. Nucleotide sequences of such inhibitor RNA oligonucleotides include portions of the following sequences: the 60 nucleotide sequence of a yeast inhibitor RNA or of

the

sequence complementary to that yeast inhibitor RNA; nucleotides 186-220 of poliovirus (stem-loop D); nucleotides 578-618 of poliovirus (stem-loop G); nucleotides 260-415 of poliovirus (stem-loop E); nucleotides 448-556 of poliovirus (stem-loop F); and the sequence of the internal ribosome entry site of the immunoglobulin heavy chain binding protein (Bip).

AN 1999:151007 USPATFULL

TI Selective inhibition of internally initiated RNA translation

IN Das, Saumitra, Los Angeles, CA, United States

Dasgupta, Asim, Los Angeles, CA, United States

Coward, Peter, San Francisco, CA, United States

PA The Regents of the University of California, Los Angeles, CA, United States (U.S. corporation)

PI US 5989904 19991123

WO 9611211 19960418

AI US 1997-817953 19971006 (8)

WO 1995-US12615 19951011

19971006 PCT 371 date

19971006 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-321427, filed on 11 Oct 1994

DT Utility

FS Granted

EXNAM Primary Examiner: LeGuyader, John; Assistant Examiner: McGarry, Sean

LREP Morrison & Foerster, LLP

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 31 Drawing Figure(s); 17 Drawing Page(s)

LN.CNT 2103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 6 USPATFULL

AB Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic

~~transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.~~

AN 1998:36597 USPATFULL
TI Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
IN Chada, Sunil, 1542 Enchantment Ave., Vista, CA, United States 92083
Dubensky, Jr., Thomas W., 12729 via Felino, Del Mar, CA, United States 92014
PI US 5736388 19980407
AI US 1994-366522 19941230 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Chambers, Jasemine C.; Assistant Examiner: Priebe, Scott D.
LREP Kruse, Norman J., Blackburn, Robert P.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 6 USPATFULL

AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.

AN 97:117939 USPATFULL
TI Methods and compositions for inhibiting production of replication competent virus
IN Klump, Wolfgang M., Del Mar, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
PA Chiron Corporation, United States (U.S. corporation)
PI US 5698446 19971216
AI US 1994-305699 19940907 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Kruse, Norman J., Blackburn, Robert P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 6 USPATFULL

AB A method for detecting multiple subpopulations of analytes of interest in a sample employing a complementary binding moiety to each of said analytes bound to a solid support, wherein each analyte and its complementary binding moiety comprise first and second members of a specific binding pair (msbp) respectively is provided. The method includes the steps of forming a mixture of known proportions of multiple subpopulations of said complementary binding moieties, wherein each subpopulation comprises a different complementary binding moieties, contacting the sample with the mixture so that specific binding pairs are formed on the solid supports, and relating the presence of analytes of interest in the sample to the formation of specific binding pairs associated with each unique proportion of said multiple subpopulations. The method can be performed with solid supports of a single average size and a single fluorochrome and without the need for using three detection

systems (fluorescence FS & SS). Also provided is a relatively low cost flow cytometer which can be used with the subject method.

AN 96:96966 USPATFULL

TI Method and composition for the simultaneous and discrete analysis of multiple analytes

IN Lehnen, Brian C., San Carlos, CA, United States

PA Trans-Med Biotech, Incorporated, S. South Francisco, CA, United States (U.S. corporation)

PI US 5567627 19961022

AI US 1993-149129 19931105 (8)

DCD 20120923

RLI Continuation of Ser. No. US 1991-731039, filed on 16 Jul 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Saunders, David; Assistant Examiner: Chin, Christopher L.

LREP Rowland, Bertram I.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1197

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.08	34.23

FILE 'BIOSIS' ENTERED AT 18:00:16 ON 08 DEC 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 5 December 2001 (20011205/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> s 110

13535 HCV
88313 HEPATITIS
913018 C
431224 VIRUS
21258 HEPATITIS C VIRUS
(HEPATITIS(W)C(W)VIRUS)
18 IRBS
116555 INTERNAL
12725 RIBOSOME
518302 BINDING
354954 SITE
6 INTERNAL RIBOSOME BINDING SITE
(INTERNAL(W)RIBOSOME(W)BINDING(W)SITE)

L12 0 L2 AND L9